

**Horizon 2020  
Marie Skłodowska Curie Actions  
PROFILE FORM**

<b>Organization Name / Department</b>	Advanced Marker Discovery, S.L. (www.amadix.com)	<b>Organization Short Name</b>	AMADIX
<b>Organization Type</b>	<input type="checkbox"/> University <input type="checkbox"/> Public Research Centre <input type="checkbox"/> Large Scale Enterprise <input checked="" type="checkbox"/> Small and Medium Scale Enterprise	<input type="checkbox"/> Public Body <input type="checkbox"/> International NGO <input checked="" type="checkbox"/> National NGO	
<b>Research Fields</b>	<input type="checkbox"/> Chemistry <b>CHE</b> <input type="checkbox"/> Social and Human Sciences <b>SOC</b> <input type="checkbox"/> Economic Sciences <b>ECO</b> <input type="checkbox"/> Information Science and Engineering <b>ENG</b> <input type="checkbox"/> Environment and Geosciences <b>ENV</b> <input checked="" type="checkbox"/> Life Sciences <b>LIF</b> <input type="checkbox"/> Mathematics <b>MAT</b> <input type="checkbox"/> Physics <b>PHY</b>	<b><u>Sub-Fields / Keywords:</u></b> <ul style="list-style-type: none"> <li>- Biotechnology</li> <li>- Cancer, oncology</li> <li>- Diagnostics</li> <li>- IVD/Medical Device</li> </ul>	
<b>Short Description of the Organization / Department</b>	<p>Founded in 2010, Amadix is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.</p> <p>The company's products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies.</p> <p>Amadix was the winner company of South Summit 2018 edition and counts with the Seal of Excellence by the European Commission (May 2020) for the quality and innovativeness of its project ColoFast.</p>		
<b>Previous Related Projects / Research Experience</b>	<p>The Company's test pipeline includes three blood-based tests for early detection of colon, lung and pancreatic cancer.</p>		
<b>Short Description of the Project idea (if foreseeable)</b>	<p>ColoFast, the most advanced product is an innovative blood-based test for colorectal cancer (CRC) diagnosis based on a unique combination of cutting-edge biomarkers (micro-RNAs and proteins). It is indicated to screen healthy population 50 to 85 years old, for early detection of the tumour and premalignant lesions. ColoFast is expected to be commercialized in 2021.</p> <p>The proof of concept of ColoFast has been demonstrated to date in case control validation studies from four different cohorts of over 1'000 patient samples (including healthy controls, AA and CRC samples). All of them colonoscopy-verified. A European prospective study with 3'100 patients is currently undergoing collection of samples in Germany and Poland, where ColoFast diagnostic performance will be measured in parallel to FIT and colonoscopy. Amadix has been granted by H2020 with €2,8M to contribute the accomplishment of the European validation of ColoFast.</p>		

<b>Related Call</b>	H2020-MSCA (MSCA-IF-EF-SE)
<b>Contact Person</b>	LUCIA REINOSO
<b>Position in the Organization</b>	CFO (CHIEF FINANCIAL OFFICER)
<b>Tel</b>	Office +34 983 10 20 60, ext. 3011 Mobile: +34 637 89 91 47
<b>Email</b>	<a href="mailto:lreinoso@amadix.com">lreinoso@amadix.com</a>